ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,156 GBX | -0.12% |
|
+7.74% | +14.53% |
| 11:24am | AstraZeneca: encouraging results in lymphoma | CF |
| 11:06am | AstraZeneca notes positive trial results for Calquence treatment | AN |
ETFs positioned on AstraZeneca PLC
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 192 M€ | +12.61% | ||
| 5.17% | 18 M€ | +3.01% | - | |
| 4.89% | 776 M€ | +8.20% | ||
| 4.11% | 88 M€ | +10.37% | - | |
| 3.47% | 233 M€ | +8.42% | ||
| 2.74% | 4 M€ | -.--% | - | |
| 2.57% | 6 M€ | -.--% | ||
| 2.53% | 5 M€ | +6.26% | - | |
| 2.53% | 1,331 M€ | +6.86% | ||
| 1.54% | 29 M€ | +8.37% | - | |
| 1.51% | 2 M€ | +9.19% | - | |
| 1.51% | 2 M€ | -.--% | - | |
| 1.26% | 12 M€ | +15.09% | - | |
| 1.19% | 49 M€ | +4.92% | ||
| 1.16% | 10 M€ | -3.35% | - | |
| 0.97% | 7 M€ | +2.58% | - | |
| 0.89% | 31 M€ | +2.76% | - | |
| 0.86% | 276 M€ | +11.40% | - | |
| 0.70% | 277 M€ | -.--% | - | |
| 0.69% | 194 M€ | +7.33% | - | |
| 0.69% | 441 M€ | +8.89% | ||
| 0.57% | 205 M€ | -.--% | ||
| 0.54% | 284 M€ | -.--% | ||
| 0.51% | 23 M€ | -.--% | - | |
| 0.51% | 786 M€ | -.--% | ||
| 0.50% | 206 M€ | -.--% | ||
| 0.48% | 717 M€ | +5.93% | ||
| 0.43% | 273 M€ | +14.71% |
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-05-20
- Investor Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
164.3
USD
Spread / Average Target
+8.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.53% | 236B | |
| +31.58% | 699B | |
| +26.04% | 571B | |
| -4.34% | 364B | |
| +18.11% | 326B | |
| +2.14% | 286B | |
| +4.42% | 198B | |
| -11.78% | 194B | |
| -4.34% | 154B | |
| -4.44% | 149B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC
